Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis Journal Article
| Authors: | Panageas, K. S.; Elkin, E. B.; De Angelis, L. M.; Ben-Porat, L.; Abrey, L. E. |
| Article Title: | Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis |
| Abstract: | BACKGROUND. The age-adjusted incidence of primary central nervous system lymphoma (PCNSL) has increased since the 1970s, and treatment for this disease has evolved considerably. The objective of this study was to examine time trends in overall survival and disease-specific mortality in a population-based cohort of patients with PCNSL. METHODS. We identified patients diagnosed with PCNSL from 1975-1999 in the Surveillance, Epidemiology, and End Results (SEER) cancer registries. To assess time trends, year of diagnosis was classified in 5-year intervals: 1975-1980, 1981-1985, 1986-1990, 1991-1995, and 1996-1999. Overall survival distributions were estimated via Kaplan-Meier methodology and a competing risk analysis was used to assess PCNSL-specific mortality. We used information on underlying cause of death to distinguish likely immunocompetent patients from those whose PCNSL was related to human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). We also examined survival stratified by age at diagnosis. RESULTS. From 1975-1999, 2462 patients were diagnosed with PCNSL in SEER. Median survival was 4 months (95% CI 4, 5) for the entire cohort and 9 months (95% CI 8, 11) for the immunocompetent cohort (n = 1565). In the immunocompetent cohort, 965 of 1323 (73%) deaths were attributed to PCNSL. No significant time trend was observed in either overall or PCNSL-specific survival. CONCLUSIONS. Overall survival for patients with PCNSL has not improved consistently in the past three decades despite important therapeutic advances during this time. Although results from clinical trials suggest progress in the treatment of PCNSL, survival improvements are not reflected in this population-based cohort. © 2005 American Cancer Society. |
| Keywords: | adult; cancer survival; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; major clinical study; united states; human immunodeficiency virus infection; cancer incidence; cohort analysis; cancer mortality; central nervous system tumor; central nervous system neoplasms; cause of death; population research; registries; lymphoma; cancer registry; acquired immune deficiency syndrome; acquired immunodeficiency syndrome; kaplan meier method; immune deficiency; primary cns lymphoma; hiv infections; brain lymphoma; central nervous system lymphoma; population-based; seer |
| Journal Title: | Cancer |
| Volume: | 104 |
| Issue: | 11 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2005-12-01 |
| Start Page: | 2466 |
| End Page: | 2472 |
| Language: | English |
| DOI: | 10.1002/cncr.21481 |
| PUBMED: | 16240449 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 46" - "Export Date: 24 October 2012" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
576De Angelis -
163Elkin -
278Abrey -
512Panageas -
69
Ben-Porat
Related MSK Work